SCHEMBL5760976

SCHEMBL5760976

C1C[C@H](NC2CCOCC2)CN1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.42
KDM1A O60341 5/20 0.39
MAOB P27338 4/20 0.39
MAOA P21397 2/20 0.39
PRKCI P41743 1/20 0.32
EPHX1 P07099 1/20 0.31
GNAI3 P08754 1/20 0.31
GNAO1 P09471 1/20 0.31
GNAI1 P63096 1/20 0.31
MAPK1 P28482 1/20 0.31
PARP14 Q460N5 1/20 0.30
CISD1 Q9NZ45 1/20 0.30
SLC6A2 P23975 1/20 0.30
HTR1B P28222 1/20 0.30
HTR2A P28223 1/20 0.30
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877708 1.00 KCNH2 (0.42) KCNH2KDM1AMAOBMAOAPRKCI
SCHEMBL2199980 1.00 KCNH2 (0.42) KCNH2KDM1AMAOBMAOAPRKCI
Hydrochloric Acid SCHEMBL30181534 0.98 KCNH2 (0.41) KCNH2KDM1AMAOBMAOAPRKCI
SCHEMBL4239836 0.89 EPHX1 (0.39) KCNH2KDM1AMAOBMAOAEPHX1
SCHEMBL25106026 0.88 KCNH2 (0.39) KCNH2KDM1AMAOBMAOA
SCHEMBL31083073 0.88 KCNH2 (0.39) KCNH2KDM1AMAOBMAOA
SCHEMBL31082989 0.88 KCNH2 (0.39) KCNH2KDM1AMAOBMAOA
SCHEMBL30674956 0.84 KDM1A (0.34) KDM1AMAOBMAOAMAPK1
SCHEMBL4709668 0.84
SCHEMBL5778312 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660185-A2 TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2006-05-31 EP disclosed
EP-1660064-A2 TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2006-05-31 EP disclosed
EP-1638934-A1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2006-03-29 EP disclosed
WO-2005020975-A2 TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2005-03-10 WO disclosed
WO-2005021095-A2 TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2005-03-10 WO disclosed
WO-2005000811-A1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2005-01-06 WO disclosed